EUVIMEDEUVIMED entdecken
Crossref

EE369 COST-EFFECTIVENESS ANALYSIS OF BIREOCICLIB VERSUS ABEMACICLIB IN HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: COMPARING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON APPROACHES

Yu Chen, Yuanbao Xie, Xinyue Yuan, Jingjing Wu, Fei Liu, xianghui Duan, MING HU

Value in Health · 2026-06 · 29 (6) · S133

DOI: 10.1016/j.jval.2026.03.663 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Yu Chen und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Chen, Y., Xie, Y., Yuan, X., Wu, J., Liu, F., Duan, X., & HU, M. (2026). EE369 COST-EFFECTIVENESS ANALYSIS OF BIREOCICLIB VERSUS ABEMACICLIB IN HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: COMPARING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON APPROACHES. Value in Health, 29(6), S133. https://doi.org/10.1016/j.jval.2026.03.663

Vancouver

Chen Y, Xie Y, Yuan X, Wu J, Liu F, Duan X, et al. EE369 COST-EFFECTIVENESS ANALYSIS OF BIREOCICLIB VERSUS ABEMACICLIB IN HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: COMPARING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON APPROACHES. Value in Health. 2026;29(6):S133. doi:10.1016/j.jval.2026.03.663

BibTeX
@article{Chen2026,
  author = {Chen, Yu and Xie, Yuanbao and Yuan, Xinyue and Wu, Jingjing and Liu, Fei and Duan, xianghui and HU, MING},
  title = {EE369 COST-EFFECTIVENESS ANALYSIS OF BIREOCICLIB VERSUS ABEMACICLIB IN HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: COMPARING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON APPROACHES},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S133},
  doi = {10.1016/j.jval.2026.03.663}
}
Kostenlos starten →